CA2564134A1 - Antifungal drug delivery - Google Patents

Antifungal drug delivery Download PDF

Info

Publication number
CA2564134A1
CA2564134A1 CA002564134A CA2564134A CA2564134A1 CA 2564134 A1 CA2564134 A1 CA 2564134A1 CA 002564134 A CA002564134 A CA 002564134A CA 2564134 A CA2564134 A CA 2564134A CA 2564134 A1 CA2564134 A1 CA 2564134A1
Authority
CA
Canada
Prior art keywords
antifungal
concentration
antifungal composition
composition
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002564134A
Other languages
English (en)
French (fr)
Inventor
Marcel Nimni
Anant Pandya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2564134A1 publication Critical patent/CA2564134A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002564134A 2004-04-27 2005-04-25 Antifungal drug delivery Abandoned CA2564134A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/832,933 US20050238672A1 (en) 2004-04-27 2004-04-27 Antifungal drug delivery
US10/832,933 2004-04-27
PCT/US2005/014246 WO2005105072A2 (en) 2004-04-27 2005-04-25 Antifungal drug delivery

Publications (1)

Publication Number Publication Date
CA2564134A1 true CA2564134A1 (en) 2005-11-10

Family

ID=35136720

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002564134A Abandoned CA2564134A1 (en) 2004-04-27 2005-04-25 Antifungal drug delivery

Country Status (14)

Country Link
US (1) US20050238672A1 (enExample)
EP (1) EP1755575A4 (enExample)
JP (1) JP2007534764A (enExample)
KR (1) KR20070024543A (enExample)
CN (1) CN101022779B (enExample)
AU (1) AU2005237541A1 (enExample)
BR (1) BRPI0510286A (enExample)
CA (1) CA2564134A1 (enExample)
IL (1) IL178750A0 (enExample)
MX (1) MXPA06012426A (enExample)
NO (1) NO20065422L (enExample)
RU (1) RU2006141653A (enExample)
WO (1) WO2005105072A2 (enExample)
ZA (1) ZA200609821B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506139D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
MXPA05012961A (es) * 2005-11-30 2007-05-30 Fernando Ahumada Ayala Preparaciones para el cuidado de las unas que contienen clorhidrato de terbinafina.
US20090215888A1 (en) * 2006-03-02 2009-08-27 Singh Jagat Topical nail formulation
WO2008102349A2 (en) * 2007-02-21 2008-08-28 Power Paper Ltd Terbinafine formulation for iontophoresis
GB201011212D0 (en) * 2010-07-02 2010-08-18 Linde Aktiengesellshcaft Gas storage apparatus
KR20120056314A (ko) * 2010-11-24 2012-06-04 주식회사유한양행 테르비나핀 또는 그의 염을 함유하는 국소 항진균 조성물
EP2906197A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
EP2906946A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
GB201317005D0 (en) * 2013-09-25 2013-11-06 Blueberry Therapeutics Ltd Composition and methods of treatment
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
CA3034839A1 (en) * 2016-08-29 2018-03-08 Carl F. Schanbacher Methods and compositions for treating cutaneous fungal infections
US11554108B2 (en) 2016-08-29 2023-01-17 Xeropedix, Inc. Methods and compositions for treating cutaneous fungal infections
RU2699653C1 (ru) * 2019-03-22 2019-09-09 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Средство для лечения микоза ногтей
EP4041839A4 (en) * 2019-10-08 2023-10-11 Hallux, Inc. ONYCHOMYCOSIS TREATMENT COMPOSITIONS AND METHODS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382151A (en) * 1964-01-13 1968-05-07 Mavala Sa Composition for strengthening nails
DE3544983A1 (de) * 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US4820724A (en) * 1986-03-31 1989-04-11 University Of Southern California Dual phase solvent carrier system
US4894375A (en) * 1986-09-29 1990-01-16 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
FR2673537B1 (fr) * 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US5487776A (en) * 1994-03-17 1996-01-30 Nimni; Marcel Anti-fungal nail lacquer and method therefor
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5652256A (en) * 1995-06-06 1997-07-29 Knowles; W. Roy Topical composition for fungal treatment
US5814308A (en) * 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6224887B1 (en) * 1998-02-09 2001-05-01 Macrochem Corporation Antifungal nail lacquer and method using same
ATE269067T1 (de) * 1998-04-17 2004-07-15 Bertek Pharm Inc Topische formulierungen zur behandlung von nagel pilzerkrankungen
US6495124B1 (en) * 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US6281239B1 (en) * 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
GB0108082D0 (en) * 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
EP1635770B1 (en) * 2003-03-21 2009-05-27 Nexmed Holdings, Inc. Antifungal nail coat and method of use
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények

Also Published As

Publication number Publication date
EP1755575A4 (en) 2010-09-22
BRPI0510286A (pt) 2007-10-30
WO2005105072A3 (en) 2006-03-02
US20050238672A1 (en) 2005-10-27
EP1755575A2 (en) 2007-02-28
JP2007534764A (ja) 2007-11-29
KR20070024543A (ko) 2007-03-02
NO20065422L (no) 2007-01-19
IL178750A0 (en) 2007-05-15
AU2005237541A1 (en) 2005-11-10
RU2006141653A (ru) 2008-06-10
WO2005105072A2 (en) 2005-11-10
CN101022779A (zh) 2007-08-22
CN101022779B (zh) 2010-12-08
MXPA06012426A (es) 2007-03-28
ZA200609821B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
US20050238672A1 (en) Antifungal drug delivery
JP5184342B2 (ja) 外用の医薬組成物
US7094422B2 (en) Topical delivery of antifungal agents
AU2016277570A1 (en) Compositions and methods for treating diseases of the nail
MX2008011435A (es) Composicion farmaceutica para uso externo.
JP7320559B2 (ja) 組成物および治療方法
Baker et al. Progress on new therapeuties for fungal nail infections
US6986896B2 (en) Method of treating fungal conditions of the skin
CN100998575B (zh) 抗真菌指甲涂膜剂及其制备方法
US20160175335A1 (en) Antifungal combination therapy of tavaborole and efinaconazole
JP4692280B2 (ja) 抗真菌剤組成物
US20170258746A1 (en) Acetic acid/thymol compositions and their use in the treatment of onychomycosis
US11154542B2 (en) Nail lacquer composition containing ciclopirox
WO2024208750A1 (en) Tri-azole antifungal compositions
US20160175334A1 (en) Antifungal combination therapy of tavaborole and ciclopirox
JP6016085B2 (ja) 抗真菌外用組成物及び抗真菌外用組成物の適用方法
WO2005032557A1 (ja) 抗真菌組成物
US20080249088A1 (en) Topical Delivery of Antifungal Drugs
JPWO1993005776A1 (ja) トルナフタート含有液剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued